Article
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
AIDS (London, England) - 5 Sept 2003
Sirivichayakul Sunee, Ruxrungtham Kiat, Ungsedhapand Chaiwat, Techasathit Wichai, Ubolyam Sasiwimol, Chuenyam Theshinee, Emery Sean, Cooper David, Lange Joep, Phanuphak Praphan
Abstract excerpt
OBJECTIVES: To investigate genotypic drug resistance in HIV-1 subtype A/E infection associated with failure of double/triple-nucleoside reverse transcriptase (RT) inhibitor therapy. METHODS: Patients from HIV-NAT 002 [stavudine (d4T)/didanosine (ddI) dose reduction study] and HIV-NAT 003 (zidovudine (ZDV)/lamivudine (3TC) versus ZDV/3TC/ddI) whose HIV-1 RNA was > 1000 copies/ml at week 48 and/or week 96 were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.